Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: A prospective single-center study

American Journal of Roentgenology

Volumn 197, Issue 5, 2011, Pages 1221-1228

  Naswa, Niraj ^a   Sharma, Punit ^a   Kumar, Abhishek ^a   Nazar, Aftab Hasan ^a   Kumar, Rakesh ^a   Chumber, Sunil ^a   Bal, Chandrashekhar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

68Ga DOTA NOC; Conventional imaging; Gastroenteropancreatic neuroendocrine tumors; Neuroendocrine tumors; PET CT

Indexed keywords

OCTREOTIDE; OCTREOTIDE[1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID] 1 SODIUM TRIIODIDE GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOID; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GASTRINOMA; GLUCAGONOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INSULINOMA; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY;

FEMALE; GALLIUM RADIOISOTOPES; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 80054919975     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.7298     Document Type: Article

References (35)

1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97:934-959 (Pubitemid 36173145)
2. Sutliff VE, Doppman JL, Gibril F, et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 1997; 15:2420-2431 (Pubitemid 27251146)
3. Fraker DL, Jensen RT. Pancreatic endocrine tumors. In: DeVita VT, Hellman S, Rosemberg SA, eds. Cancer: principles and practice of oncology, 5th ed. Philadelphia, PA: Lippincott-Raven, 1997:1678-1704
4. Eriksson B, Oberg K, Skogseid B. Neuroendocrine pancreatic endocrine tumors: clinical findings in a prospective study of 84 patients. Acta Oncol 1989; 28:373-377 (Pubitemid 19166897)
5. Schillaci O, Spanu A, Scopinaro F, et al. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2003; 44:359-368 (Pubitemid 39586011)
6. Madeira I, Terris B, Voss M, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 1998; 43:422-427 (Pubitemid 28414926)
7. La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 1996; 429:323-333 (Pubitemid 26421392)
8. Malagelada JR, Edis AJ, Adson MA, van Heerden JA, Go VLW. Medical and surgical options in the management of patients with gastrinoma. Gastroenterology 1983; 84:1524-1532 (Pubitemid 13092101)
9. Andersen DK. Current diagnosis and management of Zollinger-Ellison syndrome. Ann Surg 1989; 210:685-703 (Pubitemid 20012429)
10. Norton JA, Collen MJ, Gardner JD. Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome. Ann Surg 1986; 204:468-479 (Pubitemid 16025363)
11. Norton JA, Shawker TH, Doppman JL. Localization and surgical treatment of occult insulinomas. Ann Surg 1990; 212:615-620
12. Howard TJ, Zinner MJ, Stabile BE, Passaro E Jr. Gastrinoma excision for cure: a prospective analysis. Ann Surg 1990; 211:9-14 (Pubitemid 20027876)
13. 3] octreotate. Eur J Nucl Med Mol Imaging 2003; 30:417-422
14. Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005; 23:70-78 (Pubitemid 41702624)
15. Lamberts SWJ, Hofland LJ, van Koetsueld PM, et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization and therapy. J Clin Endocrinol Metab 1990; 71:566-574
16. Krausz Y, Bar-Ziv J, de Jong R, et al. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors. Am J Gastroenterol 1998; 93:66-70 (Pubitemid 29065516)
17. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991; 12:450-482
18. Schillaci O, Annibale B, Scopinaro F, delle Fave GF, Colella AC. Somatostatin receptor scintigraphy of malignant somatostatinoma with indium-111-pentetreotide. J Nucl Med 1997; 38:886-887 (Pubitemid 27251978)
19. Schillaci O, Massa R, Scopinaro F. Indium-111-pentetreotide scintigraphy in the detection of insulinomas: importance of SPECT imaging. J Nucl Med 2000; 41:459-462 (Pubitemid 30133965)
20. 123I-Tyr3]- octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716-731
21. Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007; 34:982-993 (Pubitemid 46919547)
22. 68Ga for medical application. J Nucl Med 2007; 48:1741-1748
23. Krenning EP, Kwekkeboom DJ, de Jong M, et al. Essentials of peptide receptor scintigraphy with emphasis on somatostatin analog octreotide. Semin Oncol 1994; 21:6-14 (Pubitemid 24378899)
24. Lamberts SWJ, Reubi JC, Krenning EP. Somatostatin and the concept of peptide receptor scintigraphy in oncology. Semin Oncol 1994; 21:1-5 (Pubitemid 24378898)
25. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000; 41:1704-1713
26. 111In-DTPA-octreotide scintigraphy. J Nucl Med 2010; 51:875-882
27. 68Ga-DOTA-NOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010; 51:669-673
28. 68Ga-labeled peptides in tumor imaging. J Nucl Med 2005; 46(suppl 1):172S-178S
29. 3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48:508-518
30. 68Ga-DOTA- NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 2010; 37:67-77
31. 68Ga-DOTA-NOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med 2010; 51:353-359
32. Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50:5969-5977 (Pubitemid 20331408)
33. Reubi JC, Kvols L, Krenning E, Lamberts SWJ. In vitro and in vivo detection of somatostatin receptors in human malignant tissues. Acta Oncol 1991; 30:463-468
34. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J Nucl Med 2011; 52:697-704
35. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68:227-232